CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $25.56M, above the global median of $18.73M
- FinancialsAltman Z-Score 1.84: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.23BCNY332.76M · vs all stocks (USD)
Trailing P/E
72.25xRevenue (TTM)
849.67MCNY126.79M · vs all stocks (USD)
Profit Margin
3.38%Beta
0.4590xvs all stocks
52-Week Change
-17.11%vs all stocks
Market Capitalization
2.23BCNY332.76M · vs all stocks (USD)
Enterprise Value
2.68BCNY399.33M · vs all stocks (USD)
Trailing P/E
72.25xForward P/E
14.45xPrice to Sales (TTM)
2.62xPrice to Book (MRQ)
4.96xEnterprise to Revenue
3.15xEnterprise to EBITDA
17.90xGross Margin
65.84%Profit Margin
3.38%Operating Margin
7.59%Return on Assets (TTM)
4.05%Return on Equity (TTM)
9.85%Revenue (TTM)
849.67MCNY126.79M · vs all stocks (USD)
Revenue per Share (TTM)
3.45CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-6.90%Gross Profit (TTM)
560.24MCNY83.60M · vs all stocks (USD)
EBITDA (TTM)
189.81MCNY28.32M · vs all stocks (USD)
Net Income (TTM)
28.76MCNY4.29M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.89%Operating Cash Flow (TTM)
155.36MCNY23.18M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
171.27MCNY25.56M · vs all stocks (USD)
5-Year Average Dividend Yield
0.40%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
289.70MCNYFY2025 · Dec 31, 2025Revenue
870.79MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
284.04MCNYFY2025 · Dec 31, 2025Gross Profit
586.75MCNYFY2025 · Dec 31, 2025Operating Income
115.35MCNY17.21M · vs all stocks (USD)
Pre-tax Income
90.79MCNYFY2025 · Dec 31, 2025Income Tax Expense
34.36MCNYFY2025 · Dec 31, 2025Net Income
56.44MCNYFY2025 · Dec 31, 2025EBIT
112.43MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
189.81MCNYFY2025 · Dec 31, 2025Research & Development
50.80MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
251.90MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
245.51KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
21.63MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1024CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1015CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
242.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
242.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
56.44MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-31.59MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
35.43MCNYFY2025 · Dec 31, 2025Free Cash Flow
1.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
161.31MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
56.44MCNYFY2025 · Dec 31, 2025Other Non-cash Items
25.08MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.67MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-33.96MCNYFY2025 · Dec 31, 2025Purchase of Investments
-60.29MCNYFY2025 · Dec 31, 2025Sale of Investments
2.36MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-91.89MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
238.30MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-285.64MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-18.97MCNYFY2025 · Dec 31, 2025Other Financing Charges
73.24MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
6.93MCNYFY2025 · Dec 31, 2025Shares Outstanding
256.06MSharesUpdated Sep 20, 2026Float Shares
216.63MSharesUpdated Sep 20, 2026% Held by Insiders
21.02%vs all stocks
% Held by Institutions
1.73%vs all stocks
Total Cash (MRQ)
96.78MCNY14.44M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3760CNYUpdated Sep 20, 2026Total Debt (MRQ)
465.61MCNY69.48M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.8835xCurrent Ratio (MRQ)
0.9970xBook Value per Share (MRQ)
1.75CNYUpdated Sep 20, 2026Total Assets
1.64BCNY245.11M · vs all stocks (USD)
Total Current Assets
604.06MCNYFY2025 · Dec 31, 2025Total Liabilities
1.05BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.04BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
431.06MCNYFY2025 · Dec 31, 2025Total Current Liabilities
617.21MCNYFY2025 · Dec 31, 2025Cash
160.98MCNYFY2025 · Dec 31, 2025Cash Equivalents
343.81KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
161.32MCNYFY2025 · Dec 31, 2025Accounts Receivable
207.28MCNYFY2025 · Dec 31, 2025Inventory
132.91MCNYFY2025 · Dec 31, 2025Accounts Payable
62.83MCNYFY2025 · Dec 31, 2025Short-term Debt
322.38MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.52MCNYFY2025 · Dec 31, 2025Long-term Debt
238.64MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.57MCNYFY2025 · Dec 31, 2025Common Stock (Book)
256.11MCNYFY2025 · Dec 31, 2025Retained Earnings
-216.31MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
594.33MCNY88.69M · vs all stocks (USD)
Treasury Stock
62.69MCNYFY2025 · Dec 31, 202552-Week Low
6.93CNYUpdated Sep 20, 202652-Week High
15.20CNYUpdated Sep 20, 202652-Week Change
-17.11%vs all stocks
Beta
0.4590xvs all stocks
50-Day MA
8.55CNYUpdated Sep 20, 2026200-Day MA
10.50CNYUpdated Sep 20, 2026Avg 10-Day Volume
8.70MSharesUpdated Sep 20, 2026Avg 30-Day Volume
13.37MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.1200CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.66Profit Margin: 0.03
Financial Health
Altman Z-Score 1.84: grey zoneSignificant
Altman Z-Score: 1.84
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $25.56M, above the global median of $18.73MNotable
Levered free cash flow (USD): 25,557,322.441Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Benitec Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BioAge Labs, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking